Literature DB >> 16958130

Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?

John G Nutt1.   

Abstract

Continuous dopaminergic stimulation (CDS) is a treatment strategy hypothesized to avoid or reduce the motor complications of long-term levodopa therapy, motor fluctuations, and dyskinesia, by preventing or reversing sensitization induced by pulsatile dopaminergic stimulation. The CDS hypothesis is itself based on several hypotheses. First, tonic dopaminergic stimulation is physiological. Second, sensitization is undesirable and should be reversed. Third, reduction of off time and dyskinesia can be induced simultaneously. Finally, clinical studies substantiate the CDS hypothesis. The evidence for these hypotheses is reviewed, and the need for randomized clinical trials that rigorously test the CDS hypothesis is emphasized. Copyright 2006 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16958130     DOI: 10.1002/mds.21060

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  22 in total

1.  Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats.

Authors:  E Grünblatt; W J Schmidt; D K A Scheller; P Riederer; M Gerlach
Journal:  J Neural Transm (Vienna)       Date:  2010-12-25       Impact factor: 3.575

Review 2.  What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?

Authors:  Rüdiger Hilker; Angelo Antonini; Per Odin
Journal:  J Neural Transm (Vienna)       Date:  2010-12-25       Impact factor: 3.575

3.  Continuous Transdermal Delivery of L-DOPA Based on a Self-Assembling Nanomicellar System.

Authors:  Amnon C Sintov; Haim V Levy; Igor Greenberg
Journal:  Pharm Res       Date:  2017-04-12       Impact factor: 4.200

Review 4.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

Review 5.  Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson's Disease.

Authors:  Pablo Martinez-Martin; Carmen Rodriguez-Blazquez; Maria João Forjaz; Monica M Kurtis
Journal:  CNS Drugs       Date:  2015-05       Impact factor: 5.749

Review 6.  Optimising levodopa therapy.

Authors:  Giovanni Abbruzzese
Journal:  Neurol Sci       Date:  2008-12       Impact factor: 3.307

Review 7.  Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease.

Authors:  Claudine M Baldwin; Gillian M Keating
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 8.  Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection.

Authors:  Giovanni Abbruzzese; Paolo Barone; Ubaldo Bonuccelli; Leonardo Lopiano; Angelo Antonini
Journal:  Funct Neurol       Date:  2012 Jul-Sep

Review 9.  Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease.

Authors:  David A Gallagher; Anette Schrag
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 10.  Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?

Authors:  Agnès Nadjar; Charles R Gerfen; Erwan Bezard
Journal:  Prog Neurobiol       Date:  2008-09-30       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.